Usmanij EA, et al. – Researchers performed an imaging study which indicated 18F–FDG PET/CT after 1 treatment cycle is predictive of outcome to first–line chemotherapy with bevacizumab in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Moreover, this enables identification of patients at risk of treatment failure, permitting treatment alternatives such as early switch to a different therapy.